16 September 2021 - - US-based generic injectables company Meitheal Pharmaceuticals, Inc has released findings from a research collaboration with Premier Applied Sciences, the research and analytics division of Premier Inc., evaluating anticoagulant treatment on outcomes of hospitalized patients diagnosed with COVID-19, the company said.

Anticoagulants are medications that prevent blood clots. Research has shown that patients with COVID-19 are more prone to developing blood clots during the course of their illness.

Researchers found that patients on a prophylactic dose of the anticoagulants enoxaparin or heparin have shorter hospital stays, lower cost, and better clinical outcomes compared to patients on a therapeutic dose.

Moreover, when the therapeutic group is split by age, lab values suggest that younger patients are just as sick as the older group, without improved outcomes.

These findings support American Society of Hematology 2021 guidelines4 conditionally recommending prophylactic dosage of anticoagulants for thromboprophylaxis in patients with COVID-19 and suggest that differences in outcomes by treatment dosage are not due to patient age.

The research project was presented at the Premier Breakthroughs Conference in July and the fully detailed results will be published later this year.

The primary objective of the study was to describe and compare the clinical outcomes and usage of resources of hospitalized patients diagnosed with COVID-19 and to assess the effects of anticoagulant treatment on outcomes.

Secondary objectives of the study included a description and comparison of demographic, visit, hospital, and clinical characteristics between exposure groups. Data from a Special Release of the Premier Healthcare database (PHD-SR)5 was used to support all objectives.

Since 2017, Meitheal Pharmaceuticals supplies generic injectables.

Its product range, from antibiotics, anticoagulants, and muscle relaxants to drugs used in chemotherapy, represents practical solutions for countless patients around the country, as well as Meitheal's commitment to their care.